-
公开(公告)号:US20240084025A1
公开(公告)日:2024-03-14
申请号:US18273888
申请日:2022-01-21
申请人: YUHAN CORPORATION
发明人: Ju-Young PARK , Sung-Hyun CHOI , Yun-Hee CHOI , Won-Tae KIM
CPC分类号: C07K16/2878 , C07K1/22 , C07K1/34 , C07K16/32 , C07K2317/31 , C07K2317/56
摘要: Provided is a method for purifying an anti-4-1BB/anti-HER2 bispecific antibody, the method of which includes carrying out affinity chromatography with a sodium acetate buffer containing a certain inorganic salt as an elution buffer. The purification method of the presently claimed subject matter increases the elution of an antibody in the intact form, thereby being able to provide an anti-4-1BB/anti-HER2 bispecific antibody in the intact form in high purity and high yield.
-
公开(公告)号:US11919952B2
公开(公告)日:2024-03-05
申请号:US17148450
申请日:2021-01-13
申请人: Yuhan Corporation
发明人: Heyue Zhou
CPC分类号: C07K16/2803 , C07K16/2827 , C07K16/30 , C07K2317/21 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/92
摘要: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
-
3.
公开(公告)号:US11780830B2
公开(公告)日:2023-10-10
申请号:US17208887
申请日:2021-03-22
申请人: YUHAN CORPORATION
发明人: Tae Dong Han , Hee Jae Tak , Eun Kyung Kim , Su Bin Choi , Sol Park , Dong Hoon Kim , So Young Kim , Hyun Ho Choi , Tae Wang Kim , Mi Kyeong Ju , Na Ry Ha , Eui Chui Lee
IPC分类号: C07D409/04 , C07D409/14 , C07D498/04 , C07D413/14 , C07D471/04 , C07D405/14
CPC分类号: C07D409/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D498/04
摘要: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
公开(公告)号:US11655235B2
公开(公告)日:2023-05-23
申请号:US17090552
申请日:2020-11-05
申请人: YUHAN CORPORATION
发明人: Tae Han Dong , Yoo Hoi Park , Tae Kyun Kim , Jae Eun Joo , Eun Hye Jung , Jae Won Jeong , Hyun Seung Lee , Do Hoon Kim , Ji Eun Yang , Jun Chui Park , Sang Myoun Lim , Na Ry Ha , Da In Chung , Ji Yeong Gal
IPC分类号: A61P1/16 , A61P35/00 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D491/048 , C07D495/04 , A61K31/4545 , A61K31/4709 , A61K31/5377 , A61K31/4725 , A61K31/519 , A61K31/423 , A61K31/517 , A61K31/4365 , A61K31/4025 , A61K31/4355
CPC分类号: C07D401/14 , C07D207/16 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D491/048 , C07D495/04 , A61K31/4025 , A61K31/423 , A61K31/4355 , A61K31/4365 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/519 , A61K31/5377 , A61P1/16 , A61P35/00
摘要: The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said compounds may be usefully applied in the treatment and prevention of FAP-mediated diseases.
-
公开(公告)号:US20230086884A1
公开(公告)日:2023-03-23
申请号:US17822450
申请日:2022-08-26
发明人: Byoungmoon LEE , Hyunjoo LEE , Gyu Jin LEE , Su Bin CHOI , Sol PARK , Heejun KIM , Misong KIM , Young Ae YOON , Kwan Hoon HYUN , Tae Kyun KIM , Jae Young SIM , Marian C. BRYAN , Scott KUDUK , James Campbell ROBERTSON
IPC分类号: C07D401/14
摘要: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
-
公开(公告)号:US20230086795A1
公开(公告)日:2023-03-23
申请号:US17822438
申请日:2022-08-26
发明人: Hyunjoo LEE , Su Bin CHOI , Young Ae YOON , Kwan Hoon HYUN , Jae Young SIM , Marian C. BRYAN , Scott KUDUK , James Campbell Robertson , Jaekyoo LEE , Paresh Devidas SALGAONKAR , Byung-Chul SUH , Jong Sung KOH , So Young HWANG
IPC分类号: C07D401/14
摘要: Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
-
公开(公告)号:USD965984S1
公开(公告)日:2022-10-11
申请号:US29751730
申请日:2020-09-23
申请人: YUHAN CORPORATION
设计人: Sung Jin Lee
-
公开(公告)号:US20220281861A1
公开(公告)日:2022-09-08
申请号:US17704718
申请日:2022-03-25
申请人: Yuhan Corporation
发明人: Sang-Ho Oh , Ja-Heouk Khoo , Jong-Chul Lim , Seong-Ran Lee , Hyun Ju , Woo-Seob Shin , Dae-Gyu Park , Su-Min Park , Yoon-Ah Hwang
IPC分类号: C07D413/14
摘要: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.
-
公开(公告)号:US11434224B2
公开(公告)日:2022-09-06
申请号:US17056557
申请日:2019-05-16
申请人: YUHAN CORPORATION
发明人: Ja-Heouk Khoo , Doo-Byung Lee , Jun-Sup Lee , Hyun Ju , Woo-Seob Shin
IPC分类号: C07D403/04 , C07D239/47
摘要: Provided are a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist, crystalline forms of a hydrochloride of the diaminopyrimidine derivative, and processes for preparing the same.
-
10.
公开(公告)号:US11168073B2
公开(公告)日:2021-11-09
申请号:US16712660
申请日:2019-12-12
申请人: YUHAN CORPORATION
发明人: Tae Dong Han , Hee Jae Tak , Eun Kyung Kim , Eui Chul Lee , Sol Park , Hyok Jun Cho , Cheol Hee Lim , So Young Kim , Hyun Ho Choi , Da Na Jeong , Na Yeon Yang , Na Ry Ha
IPC分类号: C07D403/10 , C07D249/12 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/06 , C07D409/14 , C07D413/14
摘要: The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
-
-
-
-
-
-
-
-
-